Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Analysts at Wedbush

Wedbush began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $224.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2023 earnings at $0.04 EPS, FY2023 earnings […]

Related Keywords

Douglass Ingram ,Richard Barry ,Dimensional Fund Advisors ,Needham Company ,Sarepta Therapeutics Company Profile ,Great West Life Assurance Co ,Sarepta Therapeutics Inc ,Securities Exchange Commission ,Healthcare Of Ontario Pension Plan Trust Fund ,Financial Services Group Inc ,Metlife Investment Management ,Cantor Fitzgerald ,Morgan Stanley ,Sarepta Therapeutics ,Free Report ,Marketbeat Ratings ,Moderate Buy ,Therapeutics Stock Down ,Get Free Report ,Director Richard Barry ,Exchange Commission ,Services Group ,Ontario Pension Plan Trust Fund ,Life Investment Management ,West Life Assurance ,Fund Advisors ,Sarepta Therapeutics Daily ,Nasdaq Srpt ,Srpt ,Medical ,Initiated Coverage ,Wedbush ,